Novo Nordisk’s ocedurenone Phase III flop costs company $816m
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
AstraZeneca has highlighted both the economic and environmental benefits of implementing early, targeted screening for chronic kidney disease (CKD). CKD…
Travere Therapeutics has signed a licensing agreement for sparsentan with Japan-based Renalys Pharma for multiple Asian countries. As per the…
Novartis plans to discuss the filing of its drug iptacopan in C3 glomerulopathy with global health authorities on the back…
Ipspen and Genfit’s elafibranor has received priority review designation from the US Food and Drug Administration (FDA) for the treatment…
Travere Therapeutics has implemented a 20% reduction of its workforce to funnel resources into Filspari’s (sparsentan) launch in IgA nephropathy…
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Ardelyx’s Xphozah (tenapanor) for the treatment…
I-Mab and HI-Bio have received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the investigational CD38…
The US Food and Drug Administration (FDA) approved Ardelyx’s Xphozah (tenapanor) as an add-on therapy for CKD patients on dialysis…
Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for Rivfloza (nedosiran) by injection to reduce urinary…